NewslettersHuman Immunology NewsRapamycin-Resistant Polyclonal Th1/Tc1 Cell Therapy (RAPA-201) Safely Induces Disease Remissions in Relapsed, Refractory Multiple MyelomaBy Jamie Kang - February 4, 2025011The clinical trial evaluated RAPA-201 therapy in combination with fludarabine-sparing low-dose host conditioning for the treatment of patients with relapsed, refractory multiple myeloma.[Journal For Immunotherapy of Cancer]Full Article